About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2024-12-24
First Chinese Patient Dosed for Phase 3 MRCT on ER+/HER2- Breast Cancer of HLX78
2024-12-20
Latest Results of Serplulimab in The Field of Pancreatic Cancer Released In APA/JPS/CAP/IAP 2024 Annual Meeting in Oral Presentation
2024-12-19
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
2024-12-17
Henlius Becomes Newest Member of Biosimilars Forum
2024-12-16
Latest Results of Serplulimab in The Neoadjuvant Treatment of ESCC Released In 2024 ESMO IO
2024-12-09
Latest Results of 5 Clinical Trials Released at ESMO Asia 2024
2024-12-04
Henlius Receives IND Approval from NMPA for a Phase 1b/2 Clinical Trial of Its Novel PD-L1-Targeting ADC HLX43
2024-12-04
Henlius Receives Approval form NMPA for a Phase 2 Clinical Trial of Its Novel Anti-HER2 mAb HLX22
2024-12-04
China NMPA Accepts Henlius' NDA for HLX11, an Pertuzumab Biosimilar Candidate
1
2
3
...
39
